Use of the Cannabinoid Nabilone for the Promotion of Sleep in Chronic, Non-Malignant Pain Patients

Inclusion Criteria * History of insomnia and chronic, non-malignant pain. * Patient not currently being prescribed opiates for pain management * Subject has no known clinically significant abnormal vital signs or other significant clinical findings at screening. Exclusion criteria * Patients with a history of sensitivity of cannabinoids. * Patients currently taking hypnotics, psychotomimetic substances, CNS depressants or tricyclic antidepressants that may increase the CNS-depressant effects of nabilone. * Patients with active cardiac disease or respiratory disorders. * Patients with a history of psychotic reactions, schizophrenia, bipolar disorder or any serious untreated mental disorder. * Presence of untreated sleep disorder (other than insomnia) as detected using the screening overnight PSG. * Alcohol or substance abuse (according to DSM-IV) during the last 6 months prior to baseline. * Patients with liver disease that may interfere with the clearance of nabilone. * Patients who are nursing, pregnant or likely to become pregnant throughout the course of the study. During the study, female patients will be asked to use an effective method of birth control.